Epidemic response group to invest up to $384 mln in Novavax's coronavirus vaccine
BY Reuters
— 4:04 PM ET 05/11/2020

May 11 (Reuters) - The Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million to support the development and production of Novavax Inc's ( NVAX
Loading... Loading...
) vaccine candidate against the coronavirus, the company said on Monday.

CEPI, which was set up to fight emerging epidemics, said in March it will invest $4.4 million into deals with Novavax ( NVAX
Loading... Loading...
) and Britain's University of Oxford to develop potential vaccines against COVID-19.

CEPI has so far invested in the development of six vaccine candidates against COVID-19, including projects with the U.S. firms CureVac, Inovio Pharmaceuticals ( INO
Loading... Loading...
), Moderna ( MRNA
Loading... Loading...
), and with the University of Queensland in Australia. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)